
CURIS INC
CURIS INC (CRIS)
WebsitePrice
Market cap
Next catalystInitial CLL data in December 2026emavusertib (CA-4948) + zanubrutinib — TakeAim CLL · Phase 2 dataCompany source ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Disease and market context
Detailed science focus
Detailed science focus
Background, answer, next evidence
Clinical
Upcoming clinical milestones
PreINDP1P2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
Partner / License out
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved / commercial
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved